Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion
February 24th, 2021
3K views
This protocol presents a device that produces PRP to boost the in vitro expansion of cells in a 100% autologous fibroblast culture system.
Overview
This protocol describes an autologous system for human fibroblast culture utilizing the patient's own platelet-rich plasma (PRP). The method promotes significant cell expansion in a safe manner, making it suitable for autologous cell therapies.
Key Study Components
Area of Science
- Cell culture
- Regenerative medicine
- Autologous therapies
Background
- Platelet-rich plasma (PRP) is derived from the patient's own blood.
- PRP is known to enhance cell proliferation and viability.
- Fibroblasts play a crucial role in wound healing and tissue repair.
- Using autologous materials minimizes the risk of immune rejection.
Purpose of Study
- To establish a reliable method for fibroblast expansion using PRP.
- To ensure the integrity and cleanliness of PRP before use.
- To provide a standardized protocol for researchers in regenerative medicine.
Methods Used
- Preparation of PRP from the patient's blood.
- Standardized five-minute preparation protocol.
- Careful transfer of PRP to maintain integrity.
- Monitoring of PRP for the absence of red blood cells.
Main Results
- Significant cell expansion of fibroblasts was achieved.
- PRP was effective as a cell supplement in culture.
- The method demonstrated safety for autologous applications.
- PRP integrity was maintained throughout the process.
Conclusions
- This protocol provides a robust method for fibroblast culture.
- Using PRP enhances cell expansion for therapeutic applications.
- Standardization ensures reproducibility and safety in research.
Frequently Asked Questions
What is PRP?
PRP stands for platelet-rich plasma, a concentration of platelets derived from the patient's own blood.
Why use autologous PRP?
Using autologous PRP minimizes the risk of immune rejection and enhances safety in cell therapies.
How long does the PRP preparation take?
The PRP preparation takes approximately five minutes using the standardized protocol.
What should be checked before using PRP?
It is important to check the PRP for integrity and ensure there are no red blood cells present.
Can this method be used for other cell types?
While this protocol is focused on fibroblasts, similar principles may apply to other cell types with appropriate adjustments.
Is this method safe for clinical applications?
Yes, the use of autologous PRP is considered safe for clinical applications in regenerative medicine.
Executive Industry Relevance
Autologous platelet-rich plasma (PRP) offers a potent, xenogeneic-free supplement for expanding human fibroblasts in vitro, addressing key limitations of fetal bovine serum (FBS) such as infectious risk and batch variability. By enabling rapid, standardized cell expansion using the patient’s own blood components, this method supports scalable production for autologous cell therapies in regenerative medicine. The approach enhances predictive confidence in preclinical models by providing a clinically relevant, patient-derived culture system that reduces biological variability and improves translational continuity.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of fibroblast proliferation pathways using an autologous, patient-matched supplement that reflects physiological conditions.
- Operational Value: Reduces reliance on xenogeneic serum, minimizing variability and contamination risk in early-stage target validation assays.
- Predictive Value: Supports mechanistic de-risking by demonstrating a 7.7-fold increase in fibroblast expansion over FBS, indicating strong bioactive potential.
Screening & Assay Development
- Scientific Value: Provides a standardized, reproducible PRP preparation method that yields consistent fibroblast growth metrics for assay optimization.
- Operational Value: The CuteCell-PRP device enables one-step, sterile, closed-system PRP isolation in 5 minutes, supporting high-throughput preparation for screening campaigns.
- Assay Readiness: PRP supplementation allows quantitative readouts of cell proliferation and morphological activation (e.g., F-actin reorganization via phalloidin staining) for robust compound or condition testing.
Translational & Preclinical Research
- Scientific Value: Uses autologous human fibroblasts expanded in PRP to model patient-specific responses, improving relevance of preclinical efficacy and safety assessments.
- Operational Value: Enables seamless transition from discovery to preclinical work by maintaining culture conditions that avoid xenogeneic substances.
- Risk Mitigation: Supports genomic stability assessment (e.g., via comparative genomic hybridization) to de-risk long-term culture effects before clinical application.
Pipeline & Workflow Integration
This method fits within the discovery-to-preclinical continuum, particularly in lead identification and preclinical validation stages where scalable, safe, and reproducible human cell expansion is required.
- Discovery Biology: Supports hypothesis testing on fibroblast activation and proliferation pathways using a physiologically relevant, autologous supplement.
- Screening: Delivers standardized, quantifiable outputs (viable cell count, confluence, morphological changes) essential for comparing culture conditions.
- Analytics: Enables measurement of proliferation fold-change (up to 7.7x vs FBS) and activation markers, providing data-driven criteria for go/no-go decisions.
- Translational Research: Uses patient-derived cells and autologous serum to enhance preclinical-to-clinical continuity, particularly for skin repair and tissue engineering applications.
- Enterprise Reuse: The PRP preparation protocol is adaptable to other adherent cell types (e.g., keratinocytes, mesenchymal stem cells), supporting platform-wide standardization.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in fibroblast behavior by using autologous, bioactive PRP that avoids xenogeneic confounders.
- Operational Value: Ensures reproducibility through a closed, standardized, 5-minute PRP preparation requiring only a centrifuge and dedicated device.
- Strategic Value: Reduces late-stage biological risk by enabling safer, more physiologically relevant cell expansion for autologous therapies.
- Portfolio Impact: Facilitates risk-adjusted advancement by providing a scalable, GMP-compatible method for ex vivo cell expansion.
Implementation Considerations
- Requires training in aseptic tissue handling, PRP integrity verification (absence of RBCs), and enzymatic digestion protocols.
- Needs access to a centrifuge, CuteCell-PRP or equivalent closed-system PRP device, biosafety cabinet, and standard cell culture incubators.
- Demands standardization across teams for PRP collection, resuspension (20 gentle inversions), and transfer to avoid platelet activation or contamination.
- Must account for donor variability in platelet yield and adjust PRP concentration (1–50%) based on empirical optimization for target cell type.
- Limited to adherent cell types that respond to PRP-mediated activation; not suitable for suspension cultures without modification.
Biopharma FAQs
Why does PRP concentration matter for fibroblast proliferation assays?
PRP concentration directly influences fibroblast expansion, with 20% PRP showing higher viable cell numbers than FBS after seven days of culture. The protocol demonstrates a dose-dependent effect, where PRP concentrations from 1% to 50% were tested to identify optimal proliferation boosting. This enables researchers to titrate PRP for consistent, quantitative readouts in screening and validation workflows.
How does PRP integrity affect the reliability of fibroblast expansion data?
PRP integrity is critical; the presence of red or white blood cells can introduce variability and confound proliferation results. The method emphasizes checking PRP for cleanliness and absence of RBCs before use, ensuring that observed effects are due to platelet-derived factors. Maintaining PRP quality supports reproducible, mechanistically interpretable data across experiments.
What quantitative outputs enable comparison between PRP and FBS in fibroblast culture?
Key outputs include viable fibroblast count per cm², confluence percentage (70–80% triggering passaging), and fold-expansion relative to FBS (up to 7.7x with PRP). Morphological activation via F-actin reorganization (phalloidin staining) provides a secondary metric for fibroblast phenotype. These measurements allow direct, data-driven comparison of culture supplements.
Why is replication important when validating PRP as a cell culture supplement?
Replication across multiple donors (the study used PRP from 10 different patients) ensures that the proliferative effect is consistent and not donor-specific. The mean platelet concentration in PRP was ~50% higher than whole blood across replicates, supporting robust, generalizable conclusions. This reduces false positives and strengthens confidence in PRP’s efficacy as a scalable supplement.
What statistical analysis is recommended before implementing PRP in fibroblast expansion workflows?
Before implementation, researchers should compare PRP-supplemented cultures against FBS controls using viable cell counts and statistical tests (e.g., t-test or ANOVA) to confirm significant proliferation enhancement. The study assessed proliferation over seven days without medium change, enabling endpoint comparison. Such analysis ensures that observed effects are statistically valid and not due to random variation, supporting go/no-go decisions in assay development.
